Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

110.90EUR
11:35am EST
Change (% chg)

€2.20 (+2.02%)
Prev Close
€108.70
Open
€109.75
Day's High
€112.50
Day's Low
€107.65
Volume
245,779
Avg. Vol
103,274
52-wk High
€129.85
52-wk Low
€71.01

Chart for

About

Ipsen SA is a France-based pharmaceutical company. The Company is focused on various therapeutic areas, including onocology, endocrinology, neurosciences and primary care. Its onocology portfolio includes Somatuline, Decapeptyl, Hexvix and Cabometyx. Its endocrinology portfolio includes Increlex and NutropinAq. Its primary care... (more)

Overall

Beta: 0.71
Market Cap(Mil.): €9,097.41
Shares Outstanding(Mil.): 83.69
Dividend: 0.85
Yield (%): 0.78

Financials

  Industry Sector
P/E (TTM): -- 33.55 16.42
EPS (TTM): -- -- --
ROI: -- 15.06 33.31
ROE: -- 16.59 17.56

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

Jan 16 2018

BRIEF-Ipsen Appoints Richard Paulson Executive VP And CEO Of Ipsen North America

* IPSEN APPOINTS RICHARD PAULSON EXECUTIVE VICE-PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IPSEN NORTH AMERICA Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Jan 12 2018

BRIEF-Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​

* ‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​

Nov 29 2017

BRIEF-Ipsen ‍reports Q3 2017 group sales growth of 22.6%​

* Q3 GROUP SALES EUR ‍​470.1 MILLION VERSUS EUR 390.6 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 26 2017

BRIEF-Ipsen announces success of phase 3 CELESTIAL trial of Cabozantinib

* IPSEN ANNOUNCES THAT PHASE 3 CELESTIAL TRIAL OF CABOZANTINIB MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

Oct 16 2017

BRIEF-Ipsen receives approval from European Commission for Xermelo

* Ipsen receives approval from European Commission for Xermelo® (Telotristat Ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

Sep 19 2017

BRIEF-FDA approves new indication for Ipsen's somatuline depot injection

* U.S. FDA approves new indication for Ipsen's somatuline® depot (lanreotide) injection for the treatment of carcinoid syndrome Source text for Eikon: Further company coverage:

Sep 18 2017

BRIEF-Ipsen annouces US FDA approval of new indication for Somatuline Depot

* U.S. FDA APPROVES NEW INDICATION FOR IPSEN'S SOMATULINE DEPOT (LANREOTIDE) INJECTION FOR THE TREATMENT OF CARCINOID SYNDROME Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 18 2017

BRIEF-Ipsen receives validation from European Medicines Agency for application of new indication for Cabometyx

* ANNOUNCED ON FRIDAY, IPSEN RECEIVES VALIDATION FROM EUROPEAN MEDICINES AGENCY FOR THE APPLICATION OF A NEW INDICATION FOR CABOMETYX (CABOZANTINIB) FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN ADULTS

Sep 11 2017

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

Sep 11 2017

Earnings vs. Estimates